Bright Minds Biosciences Inc. (DRUG) Income Statement

The company's revenue line is consistently zero, confirming its early-stage clinical focus. The primary trajectory is the significant ramp-up in research and development spending, which appears to be driven by the progression of its lead candidate, BMB-101, into more advanced clinical trials. This acceleration in R&D spend is a necessary precursor to potential future revenue but also dramatically increases the quarterly cash burn rate.

With no cost of goods sold, the company's expenses are split between R&D and SG&A. The R&D line item has grown from a negligible $105.2K in 2024Q2 to $9.5M in 2026Q3, suggesting a major scaling of clinical trial activities. SG&A has remained relatively controlled, growing from $363.6K to $2.2M over the same period, which implies management is maintaining administrative discipline while funneling capital into the pipeline.

Operating income has deteriorated in lockstep with the increase in R&D spending, demonstrating that the business is not yet generating any revenue to offset its growing cost base. This is typical for a clinical-stage biotech, but the magnitude of the loss expansion underscores the high-risk, capital-intensive nature of drug development. The lack of operating leverage will persist until a product receives approval and generates meaningful sales.

Prior to 2025, R&D spending was minimal, suggesting the company was in an earlier, less capital-intensive research phase. The step-change in 2025Q1, where R&D hit $1.0M, and the subsequent acceleration, marks the point where the company committed significant capital to human trials. This inflection point is critical as it defines the current high-burn phase and sets the timeline for potential data readouts that could drive future valuation.